Evidence map›Paper›PMID 41926032›Full record

ArticleNeurology and therapy2026

Exploring Preferences and Priorities in Advanced Parkinson's Disease: A Discrete Choice Experiment.

Pablo Arija, Josefa Domingos, Irene A Malaty, Rajesh Pahwa, K Ray Chaudhuri, Angelo Antonini, Hannah Penton, Marieke Heisen, Connie H Yan, Pavnit Kukreja and 5 more

Abstract read
In one paragraph

Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Pablo ArijaPatient-Centered Outcomes, OPEN Health, Marten Meesweg 107, 3068 AV, Rotterdam, The Netherlands. pabloarija@openhealthgroup.com.ORCID http://orcid.org/0000-0003-2099-9723
Josefa DomingosParkinson's Europe, Orpington, UK.ORCID http://orcid.org/0000-0001-9390-6183
Irene A MalatyDepartment of Neurology, University of Florida, Norman Fixel Institute for Neurological Diseases, Gainesville, FL, USA.ORCID http://orcid.org/0000-0001-6914-9223
Rajesh PahwaUniversity of Kansas Medical Center, Kansas City, KS, USA.ORCID http://orcid.org/0000-0003-3176-6466
K Ray ChaudhuriKings College Hospital London, Dubai, UAE.ORCID http://orcid.org/0000-0003-2815-0505
Angelo AntoniniNeurodegenerative Disease Unit, Centre for Rare Neurological Diseases (ERN-RND), Department of Neuroscience, University of Padova, Padua, Italy.ORCID http://orcid.org/0000-0003-1040-2807
Hannah PentonPatient-Centered Outcomes, OPEN Health, Marten Meesweg 107, 3068 AV, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0001-9492-7875
Marieke HeisenPatvocates, Munich, Germany.ORCID http://orcid.org/0000-0002-5339-6606
Connie H YanAbbVie, Inc., North Chicago, IL, USA.ORCID http://orcid.org/0000-0003-1467-4666
Pavnit KukrejaAbbVie, Inc., North Chicago, IL, USA.
Elaheh ShirneshanAbbVie, Inc., North Chicago, IL, USA.
Inyoung LeeAbbVie, Inc., North Chicago, IL, USA.ORCID http://orcid.org/0000-0001-5436-2013
Megha ShahAbbVie, Inc., North Chicago, IL, USA.
Juan Carlos ParraAbbVie, Inc., North Chicago, IL, USA.
Marco BoeriPatient-Centered Outcomes, OPEN Health, London, UK.ORCID http://orcid.org/0000-0001-7346-2132

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTreatments for advanced Parkinson's disease (aPD) are differentiated by efficacy, safety, and modality-related characteristics. As the disease progresses and motor fluctuations worsen, many patients require more frequent dosing or consideration of device-aided therapies, including subcutaneous infusions, intestinal gel delivery systems, or deep brain stimulation. Assessing treatment preferences is valuable to ensure people with aPD (PwP) and care partners (CPs) are satisfied with a treatment's impact on both motor function and quality of life, potentially increasing adherence and effectiveness.

methodsA total of 304 participants (223 PwP, 81 CPs) from the USA, UK, and Germany were included in the study. A discrete choice experiment (DCE) was used to elicit preferences over treatment characteristics. In the DCE, respondents were presented with a series of choice tasks, each consisting of two hypothetical treatments described by varying levels of seven attributes: daily hours of ON time without troublesome dyskinesia (ONwoTD), frequency of early morning OFF time (EMO), risk of mild-to-moderate skin reactions, risk of severe side effects requiring hospitalization, route of administration (ROA), frequency of pill regimen, and frequency of device maintenance. Analyses with a random parameter logit model were used to estimate attribute conditional relative importance (CRI) and explore how people would trade off across attributes.

resultsThe average PwP age was 65.7 years (SD 8.6), time since diagnosis was 10.0 years (SD 4.4), and self-reported OFF time was 4.0 h/day (SD 2.4). Within the survey design, ROA emerged as the most important attribute (CRI 35.3), followed by hours of ONwoTD (CRI 26.4). All other attributes were of similar importance. Nonsurgical treatments were strongly preferred, with oral pills being the most preferred, followed by infusion device without surgery (subcutaneous infusion).

conclusionsPwP prioritized efficacy (ONwoTD) and ROA when considering treatment options. Understanding these preferences may enhance informed and meaningful decision-making between healthcare providers and PwP.

Indexed as

Advanced Parkinson’s diseaseAttribute relative importanceBenefit–risk trade-offsDiscrete choice experimentNeurologyPatient-centered carePatient preference

Identifiers

PMID41926032
PMCPMC13172160

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.